Sven Perner Selected Research

Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)

10/2015	Fibroblast growth factor receptor 1 gene amplification in gastric adenocarcinoma.
9/2014	Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer.
5/2014	A new bright-field dual-colour chromogenic and silver in situ hybridization method for the detection of FGFR1 gene copy number status.
10/2013	Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck.
8/2013	Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
1/2013	Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.
10/2012	Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.
12/2010	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sven Perner Research Topics

Disease

110	Neoplasms (Cancer) 09/2022 - 05/2006
67	Prostatic Neoplasms (Prostate Cancer) 04/2022 - 10/2005
24	Squamous Cell Carcinoma of Head and Neck 09/2022 - 10/2013
20	Neoplasm Metastasis (Metastasis) 01/2022 - 03/2007
15	Lung Neoplasms (Lung Cancer) 09/2021 - 12/2010
12	Lymphatic Metastasis 01/2022 - 09/2006
9	Carcinoma (Carcinomatosis) 05/2022 - 01/2013
9	Carcinogenesis 04/2022 - 11/2009
8	Disease Progression 01/2019 - 03/2010
7	Adenocarcinoma 02/2022 - 11/2009
7	Renal Cell Carcinoma (Grawitz Tumor) 09/2021 - 01/2015
5	Head and Neck Neoplasms (Head and Neck Cancer) 03/2022 - 01/2016
5	Inflammation (Inflammations) 03/2022 - 01/2015
5	Melanoma (Melanoma, Malignant) 01/2019 - 03/2010
5	Adenocarcinoma of Lung 01/2017 - 12/2007
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 12/2016
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2013 - 11/2009
3	Squamous Cell Neoplasms (Squamous Cell Cancer) 09/2022 - 10/2013
3	Breast Neoplasms (Breast Cancer) 09/2022 - 12/2015
3	Margins of Excision 06/2021 - 01/2009
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 01/2014
2	Hypoxia (Hypoxemia) 03/2022 - 12/2016
2	Colorectal Neoplasms (Colorectal Cancer) 03/2022 - 01/2013
2	Chromothripsis 12/2021 - 08/2015
2	Arthritis (Polyarthritis) 01/2018 - 01/2015
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2017 - 09/2015
2	Polyploidy 04/2015 - 01/2014
1	Oropharyngeal Neoplasms 06/2022
1	7 Hereditary Prostate Cancer 01/2022

Drug/Important Bio-Agent (IBA)

33	Proteins (Proteins, Gene)FDA Link 06/2022 - 01/2008
29	Biomarkers (Surrogate Marker)IBA 06/2022 - 11/2008
16	Androgen Receptors (Androgen Receptor)IBA 02/2022 - 06/2008
14	AndrogensIBA 04/2022 - 10/2005
13	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 09/2006
10	Transcription Factors (Transcription Factor)IBA 05/2022 - 03/2007
10	Messenger RNA (mRNA)IBA 01/2022 - 06/2011
9	Immune Checkpoint InhibitorsIBA 09/2022 - 01/2018
9	Hormones (Hormone)IBA 02/2022 - 09/2006
9	Prostate-Specific Antigen (Semenogelase)IBA 01/2015 - 05/2006
8	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 10/2015 - 12/2010
7	RNA (Ribonucleic Acid)IBA 03/2022 - 08/2009
7	Biological ProductsIBA 01/2022 - 10/2007
6	ParaffinIBA 09/2022 - 11/2009
6	Formaldehyde (Formol)FDA Link 09/2022 - 09/2011
6	AntigensIBA 05/2022 - 05/2007
6	Tyrosine Kinase InhibitorsIBA 01/2021 - 06/2014
6	Phosphotransferases (Kinase)IBA 07/2020 - 09/2013
6	Mediator ComplexIBA 01/2020 - 01/2014
5	ST 679IBA 01/2017 - 01/2014
5	Proto-Oncogene Proteins c-etsIBA 02/2013 - 10/2005
4	Histones (Histone)IBA 01/2019 - 06/2014
4	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 10/2014 - 10/2012
3	AntibodiesIBA 09/2022 - 01/2017
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 07/2020
3	B7-H1 AntigenIBA 01/2021 - 01/2021
3	ErbB Receptors (EGF Receptor)IBA 01/2017 - 12/2010
3	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 07/2014
3	ChromatinIBA 02/2016 - 12/2010
3	Long Noncoding RNAIBA 09/2015 - 01/2015
2	Histone DemethylasesIBA 05/2022 - 04/2022
2	ElementsIBA 04/2022 - 01/2022
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2022 - 11/2009
2	Protein Isoforms (Isoforms)IBA 10/2021 - 08/2008
2	Hemoglobins (Hemoglobin)IBA 06/2021 - 06/2021
2	Hematoxylin (Haematoxylon)IBA 01/2021 - 04/2020
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 01/2017
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2021 - 04/2020
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2021 - 01/2021
2	Lysine (L-Lysine)FDA Link 01/2019 - 09/2014
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2018 - 01/2017
2	Monoclonal AntibodiesIBA 02/2017 - 01/2017
2	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 11/2016
2	Estrogens (Estrogen)FDA Link 01/2017 - 06/2008
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2016 - 11/2016
2	Interleukin-6 (Interleukin 6)IBA 04/2016 - 07/2015
2	StaurosporineIBA 04/2015 - 01/2014
2	prosteinIBA 01/2015 - 02/2013
2	LigandsIBA 10/2014 - 12/2007
2	ponatinibIBA 10/2014 - 06/2014
2	Anaplastic Lymphoma KinaseIBA 09/2014 - 12/2010
2	MucinsIBA 03/2014 - 07/2009
2	Pharmaceutical PreparationsIBA 01/2013 - 11/2011
2	Complementary DNA (cDNA)IBA 06/2011 - 06/2008
1	Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidaseIBA 09/2022
1	BuffersIBA 05/2022
1	Blocking AntibodiesIBA 03/2022
1	Nuclear Pore Complex Proteins (Nucleoporins)IBA 01/2022
1	Keratins (Keratin)IBA 01/2022
1	Cadherins (E-Cadherin)IBA 01/2022
1	Adenine FDA LinkGeneric 01/2022

Therapy/Procedure

34	Therapeutics 03/2022 - 05/2007
17	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 10/2007
17	Castration 01/2022 - 12/2010
4	Radiotherapy 03/2022 - 01/2018
3	Drug Therapy (Chemotherapy) 02/2021 - 11/2016
2	Precision Medicine 01/2021 - 12/2016
2	Immunotherapy 02/2017 - 05/2016
2	Combined Modality Therapy 10/2015 - 09/2014
2	Aftercare (After-Treatment) 02/2012 - 06/2008
2	Ligation 06/2011 - 06/2008